ESR1 and breast cancer: In this study, a loss of Erα expression in recurrent BC was associated with a poor clinical benefit from ETs, with only 12.5% of patients with ERα− tumors responding to tamoxifen-based therapy (compared with 74% of patients retaining intratumor Erα expression).